Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 93,710,000, an increase of 13.4% compared to RMB 82,502,000 for the same period in 2023[7]. - Gross profit for the same period was RMB 53,756,000, up from RMB 51,364,000, reflecting a gross margin improvement[7]. - Loss before tax increased to RMB 82,730,000, compared to RMB 40,529,000 in the prior year, indicating a significant rise in operational challenges[7]. - Loss for the period was RMB 81,488,000, compared to RMB 41,017,000 in 2023, highlighting ongoing financial difficulties[7]. - Basic and diluted loss per share was RMB (0.79), worsening from RMB (0.36) in the previous year[7]. - Total comprehensive loss for the period was RMB 82,055,000, compared to RMB 42,217,000 in the same period last year, indicating worsening financial performance[185]. - The company reported a loss for the period of RMB 80,502,000 for the six months ended June 30, 2024, compared to a loss of RMB 40,529,000 for the same period in 2023, reflecting an increase in losses of approximately 98.5%[190]. Assets and Liabilities - Non-current assets increased to RMB 529,749,000 from RMB 402,985,000, indicating growth in long-term investments[7]. - Current assets decreased to RMB 1,017,620,000 from RMB 1,281,927,000, suggesting a reduction in short-term liquidity[7]. - Current liabilities decreased to RMB 61,791,000 from RMB 110,237,000, reflecting improved short-term financial management[7]. - Total equity attributable to equity shareholders was RMB 1,455,242,000, down from RMB 1,540,383,000, indicating a decline in shareholder value[7]. - The net assets of the company as of June 30, 2024, were RMB 1,471,627,000, down from RMB 1,557,784,000 at the end of 2023, indicating a decline of about 5.5%[63]. - The company recorded an impairment of trade receivables amounting to approximately RMB 24.7 million for the six months ended June 30, 2024, mainly related to a loss allowance for a contract of sales of laser myopia treatment devices[31]. Revenue Streams - Revenue from Airdoc Medical rose from RMB 29.8 million to RMB 36.5 million, with a growth rate of 22.1%[15]. - Revenue from Airdoc Eye Health increased from RMB 31.0 million to RMB 38.0 million, achieving a growth rate of 22.7%[15]. - Revenue from the sale of Airdoc-AIFUNDUS (1.0) retinal cameras amounted to RMB 36.5 million, an increase of 22.1% compared to the same period last year[54]. - Revenue from Airdoc Eye Health during the Reporting Period was RMB 38.0 million[62]. Research and Development - The company has developed an integrated solution combining AI-based software and hardware for retinal detection and health risk assessment[16]. - AI-empowered treatment products for myopia, strabismus, and amblyopia have been launched, providing a one-stop solution from detection to treatment[11]. - The company plans to expand its health risk assessment solutions to cover additional health risks beyond the current offerings[30]. - Continued investment in R&D for GenAI-related technologies is planned, with strategies to incorporate GenAI into auxiliary diagnosis and personalized medical advice[68]. - R&D expenses decreased by 13.3% from RMB 56.5 million for the six months ended June 30, 2023, to RMB 49.0 million for the six months ended June 30, 2024[80]. Market Expansion and Strategy - The company aims to expand its market coverage beyond hospitals to primary healthcare institutions and consumer health environments[11]. - The company is preparing for comprehensive entry into overseas markets, including Malaysia, Singapore, Thailand, the United Arab Emirates, and South Africa, expecting gradual sales increases in these new markets[68]. - Airdoc aims to establish an AI visual training digital therapy using its in-house developed AI eye movement technology, creating a competitive advantage in ophthalmic visual health[43]. Corporate Governance - The Company has adopted the Corporate Governance Code and believes it has complied with all applicable provisions for the Reporting Period, except for the separation of roles between chairman and chief executive officer[127]. - The Company is in the process of identifying a suitable candidate to fill the vacancy of independent non-executive Director following the resignation of Mr. Albert Ng[129]. - The Board comprises four executive Directors and three independent non-executive Directors, ensuring a strong independent element in its composition as of June 30, 2024[128]. Shareholder Information - As of June 30, 2024, Mr. Zhang holds 9,109,466 H Shares, representing 17.05% of the relevant class of Shares[111]. - The total number of H Shares held by Mr. Zhang, including interests in controlled corporations, is 1,371,845, which is 2.57% of the relevant class of Shares[111]. - The Company did not purchase, sell, or redeem any listed securities during the six months ended June 30, 2024[151]. Compliance and Risk Management - The Group has complied with relevant laws and regulations that significantly impact its business operations during the Reporting Period[132]. - The company is focused on ensuring accurate financial reporting in accordance with the latest amendments[199]. - The company is actively monitoring the impact of these amendments on its financial position[200].
鹰瞳科技(02251) - 2024 - 中期财报